Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2014 Aug 15;28(16):1800–1814. doi: 10.1101/gad.244368.114

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2014 Huang et al.; Published by Cold Spring Harbor Laboratory Press

This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issue publication date (see http://genesdev.cshlp.org/site/misc/terms.xhtml). After six months, it is available under a Creative Commons License (Attribution-NonCommercial 4.0 International), as described at http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Figure 4. — MYC expression predicts response to CDK9 inhibition. (A) Scatter plot illustrating the correlation between PHA-767491 (PHA) IC₅₀ values and MYC expression levels in human HCC (red; from Fig. 3B,C), leukemia, lymphoma, and lung cancer cell lines (n = 28). (B) Scatter plot illustrating the correlation between survival with CDK9 shRNAs and MYC expression levels in a panel of different human HCC cell lines (from Fig. 2F). The survival is defined as the average of the survival ratio of two shRNAs in competitive proliferation assay. (C) Immunoblots showing MYC protein levels in 10 human HCC cell lines. β-Actin was used as loading control. (D) GSEA plot evaluating the association between low IC₅₀ of PHA-767491 and MYC targets. (NES) Normalized enrichment score; (FDR) false discovery rate. (E) GO term analysis of the genes that are significantly associated with sensitivity to PHA-767491.